Helsia Capital acquisisce il 43% di Valmed
Deal News | Jun 23, 2025 | Finance Community IT - 3 Private Equity
Helsia Capital has acquired a 43% stake in the Italian biotech company Valmed. Helsia Capital, a privately owned investment firm, was advised by Alpeggiani Avvocati Associati and Deloitte on financial and tax matters, while Valmed and its sellers were advised by Studio Mbl Pro on legal, financial, and tax aspects. Valmed, founded in Italy and employing over 110 personnel, specializes in developing, manufacturing, and distributing medical and biotech products primarily for the pharmaceutical and healthcare sectors. Since its inception, Valmed has demonstrated significant growth, starting from a revenue of 8 million euros in 2017 and surpassing 20 million euros in 2024, achieving an EBITDA over 22%. This acquisition is expected to fortify Helsia's ties with other biotech and healthcare firms, and contribute to the ambitious projects nurturing between these entities. Helsia Capital emphasizes its capability to apply its market expertise and networking assets to accelerate Valmed's progression and enhance strategic collaborations in the healthcare and biotech industries.
Sectors
- Healthcare & Biotechnology
- Investment & Private Equity
Geography
- Italy – Valmed is an Italian company engaged in the production and distribution of medical and biotech products.
- France – Thomas Schmidt, founder of Helsia Capital, was previously an investment director at the French company UI Investissement, indicating cross-national ties in investment activities.
Industry
- Healthcare & Biotechnology – Valmed operates within the healthcare and biotechnology sectors, producing medical and biotech products for pharmaceutical and healthcare applications.
- Investment & Private Equity – Helsia Capital is involved in investment activities, acquiring shares and investing in other companies like Valmed to enhance growth and collaboration.
Financials
- 20 million euros – The revenue of Valmed in 2024, showing significant growth from 8 million euros in 2017.
- 22% – The EBITDA of Valmed for the year 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Helsia Capital | Bidding Company/Buyer | Company | An investment firm that acquired a 43% stake in Valmed. |
| Valmed | Target company | Company | An Italian biotech firm involved in developing medical and biotech products. |
| Alpeggiani Avvocati Associati | Legal Advisor | Company | Provided legal advisory services to Helsia Capital. |
| Deloitte | Financial Advisor | Company | Advised Helsia Capital on financial and tax aspects of the transaction. |
| Studio Mbl Pro | Legal Advisor | Company | Advised Valmed and its vendors on legal, financial, and tax matters. |
| Techni-Pharma | Portfolio Company | Company | A pharmaceutical company previously acquired by Helsia Capital. |
| Thomas Schmidt | Founder | Person | Founder of Helsia Capital, with a background as an investment director at UI Investissement in France. |